Payment overview · 2025
General Payments
$1,049.06
61 reported records · 17 companies
Healthcare provider profile · identity verified
Mary M Hammack, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PLANO, TX · NPI 1871501874
Verified facts
What the public records show
CMS Open Payments records show Mary M Hammack, MD received $1,049.06 in general payments during 2025 across 61 reported records.
Lilly USA, LLC accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $215.60 | 20.6% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $174.42 | 16.6% | 18 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $164.03 | 15.6% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $78.87 | 7.5% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $58.16 | 5.5% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.99 | 5.0% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$50.02 | 4.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $44.17 | 4.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.49 | 4.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.82 | 3.0% | 2 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $31.20 | 3.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.56 | 2.3% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.27 | 1.7% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $17.51 | 1.7% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.56 | 1.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $14.30 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $14.09 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,049.06 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $146.75 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.43 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.43 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $79.19 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $78.87 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $59.56 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.36 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.36 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.99 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $50.33 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $50.33 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $43.49 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $33.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $31.82 | 2 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $31.20 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $19.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.52 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| O-ARM Normalized: o arm |
Device | Medtronic, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $14.30 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $13.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 21 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 573 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 475 | 131 |
| Escitalopram Oxalate | Escitalopram Oxalate | 250 | 54 |
| Amlodipine Besylate | Amlodipine Besylate | 223 | 65 |
| Losartan Potassium | Losartan Potassium | 211 | 58 |
| Gabapentin | Gabapentin | 205 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 194 | 54 |
| Lisinopril | Lisinopril | 193 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 172 | 49 |
| Omeprazole | Omeprazole | 159 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 151 | 37 |
| Trazodone Hcl | Trazodone Hcl | 149 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 40 |
| Sertraline Hcl | Sertraline Hcl | 120 | 29 |
| Synthroid | Levothyroxine Sodium | 117 | 27 |
| Furosemide | Furosemide | 111 | 33 |
| Montelukast Sodium | Montelukast Sodium | 109 | 34 |
| Simvastatin | Simvastatin | 106 | 30 |
| Alprazolam | Alprazolam | 105 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 99 | 30 |
| Alendronate Sodium | Alendronate Sodium | 94 | 31 |
| Metformin Hcl Er | Metformin Hcl | 93 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 89 | 27 |
| Carvedilol | Carvedilol | 78 | 22 |
| Donepezil Hcl | Donepezil Hcl | 77 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 32 |
| Tramadol Hcl | Tramadol Hcl | 72 | 22 |
| Valacyclovir | Valacyclovir Hcl | 72 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 23 |
| Potassium Chloride | Potassium Chloride | 60 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 24 |
| Allopurinol | Allopurinol | 58 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 15 |
| Metformin Hcl | Metformin Hcl | 57 | 14 |
| Ezetimibe | Ezetimibe | 56 | 17 |
| Eliquis | Apixaban | 54 | 13 |
| Bupropion Xl | Bupropion Hcl | 53 | 14 |
| Doxepin Hcl | Doxepin Hcl | 53 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 35 |
| Estradiol | Estradiol | 44 | 18 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 25 |
| Lorazepam | Lorazepam | 41 | 12 |
| Azithromycin | Azithromycin | 40 | 34 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Famotidine | Famotidine | 37 | 11 |
| Celecoxib | Celecoxib | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Prednisone | Prednisone | 36 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Ozempic | Semaglutide | 34 | suppressed |
| Cefdinir | Cefdinir | 32 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Ramipril | Ramipril | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Prolia | Denosumab | 21 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 16 |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Verapamil Sr | Verapamil Hcl | 16 | suppressed |
| Lyrica | Pregabalin | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 11 |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Estazolam | Estazolam | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,049.06 · 61 records | Lilly USA, LLC | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, Flector, INTELLIS ADAPTIVESTIM, ISTURISA, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Licart, MOUNJARO, O-ARM, OTEZLA, Omnipod, Ozempic, PREVNAR 20, PROCLAIM, PROLIA, PYRUKYND, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, Tirosint, UBRELVY, VENASEAL, Veozah, Wegovy, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error